PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1795370
PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1795370
Stem Cell Umbilical Cord Blood
Global Stem Cell Umbilical Cord Blood Market to Reach US$7.7 Billion by 2030
The global market for Stem Cell Umbilical Cord Blood estimated at US$2.6 Billion in the year 2024, is expected to reach US$7.7 Billion by 2030, growing at a CAGR of 19.9% over the analysis period 2024-2030. Pharmaceuticals End-Use, one of the segments analyzed in the report, is expected to record a 21.5% CAGR and reach US$4.2 Billion by the end of the analysis period. Growth in the Research Institutes End-Use segment is estimated at 17.2% CAGR over the analysis period.
The U.S. Market is Estimated at US$683.5 Million While China is Forecast to Grow at 18.7% CAGR
The Stem Cell Umbilical Cord Blood market in the U.S. is estimated at US$683.5 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$1.2 Billion by the year 2030 trailing a CAGR of 18.7% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 18.5% and 17.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 14.4% CAGR.
Global Stem Cell Umbilical Cord Blood Market - Key Trends & Drivers Summarized
What’s Driving Interest in Umbilical Cord Blood Stem Cells?
Umbilical cord blood stem cells, rich in hematopoietic and mesenchymal progenitors, have emerged as vital regenerative medicine tools. Their applications span treatments for blood disorders, immune deficiencies, and some metabolic diseases. Collecting and banking cord blood at birth has become a proactive healthcare choice for families, offering a potential autologous or allogeneic transplant source. Clinicians rely on the cells’ lower rejection rates and ethical ease-as collection is non-invasive and avoids embryonic stem cell controversies. Public cord blood banks and private storage services are collaborating with obstetric centers to simplify collection protocols. Additionally, cord blood is being explored as a stem cell source for emerging therapies in neurology, autoimmune disorders, and tissue repair, indicating an expansion pipeline beyond traditional hematology.
Are Technological Improvements Enhancing Collection and Storage?
Advanced cryopreservation solutions- using DMSO-free cryoprotectants, automated controlled-rate freezing, and optimized storage systems-are increasing cell viability post-thaw. High-throughput processing platforms are enabling standardized volume reduction, red blood cell depletion, and CD34+ enrichment. Digital tracking ensures end-to-end sample traceability-from collection kit to storage vault-helping banks comply with regulatory audits and accreditation standards. Integration with electronic health records allows physicians to quickly verify availability, matching criteria, and histocompatibility reports-facilitating pre-transplant decision-making and improving outcomes.
Why Are Families and Clinics Embracing Cord Blood Banking?
The rise in chronic and genetic pediatric disorders has elevated interest in cord blood banking as a preventative safeguard. Parents view banked cord blood as a high-value biological asset for their child and immediate family. Advances in public-private partnership banking models allow families without means to support research-accessible public banking, promoting equity. Clinicians and transplant centers prioritize cord blood units with high cell counts and optimal antigen matching. As suppliers expand outreach and educational programs, awareness around banked cord blood’s therapeutic potential is increasing.
What’s Powering the Growth in the Cord Blood Stem Cell Market?
The growth in the stem cell umbilical cord blood market is driven by several factors related to advanced cryogenic technology, expanded therapeutic use cases, and evolving healthcare policies. Over two dozen FDA-approved therapies and increasing clinical trials for neurological, autoimmune, and metabolic indications are broadening demand. Enhanced cryopreservation techniques ensure long-term viability and efficacy, enhancing patient outcomes. Government incentives and insurance coverage policies in regions like Europe, Asia-Pacific, and North America are supporting banking adoption. Partnerships between birthing centers, banks, and research institutions are streamlining collection logistics. Finally, growing public awareness of cord blood’s therapeutic value and branding trust in accredited banks are fueling both private and public storage.
SCOPE OF STUDY:
The report analyzes the Stem Cell Umbilical Cord Blood market in terms of units by the following Segments, and Geographic Regions/Countries:
Segments:
End-Use (Pharmaceuticals End-Use, Research Institutes End-Use, Hospitals End-Use, Biobanks End-Use)
Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.
Select Competitors (Total 37 Featured) -
- AlphaCord LLC
- Americord Registry
- ATCC (American Type Culture Collection)
- Celularity
- Cells4Life Group LLP
- CellResearch Corporation
- Cord Blood Registry (CBR)
- Cord Blood Registry (ViaCord, PerkinElmer)
- CordforLife
- Cordlife Group Ltd
- Cryo-Cell International
- FamiCord Group
- Global Cord Blood Corporation
- LifeCell International
- MiracleCord
- NECBB (New England Cord Blood Bank)
- PerkinElmer (ViaCord)
- Precision Cellular Storage / Virgin Health Bank
- Relicord
- StemCyte
AI INTEGRATIONS
We're transforming market and competitive intelligence with validated expert content and AI tools.
Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.
TARIFF IMPACT FACTOR
Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.
TABLE OF CONTENTS
I. METHODOLOGY
II. EXECUTIVE SUMMARY
- 1. MARKET OVERVIEW
- Influencer Market Insights
- World Market Trajectories
- Tariff Impact on Global Supply Chain Patterns
- Stem Cell Umbilical Cord Blood - Global Key Competitors Percentage Market Share in 2025 (E)
- Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
- 2. FOCUS ON SELECT PLAYERS
- 3. MARKET TRENDS & DRIVERS
- Rising Incidence of Blood-Related Disorders Drives Adoption of Cord Blood Stem Cell Therapies
- Increased Use in Transplant Procedures Strengthens Clinical Relevance of Banked Cord Blood
- Government Support and Public Banking Initiatives Expand Access and Awareness
- Technological Advancements in Cryopreservation Improve Cell Viability and Storage Duration
- Expansion of Private Cord Blood Banks Boosts Consumer Participation and Industry Funding
- Regenerative Medicine Developments Propel Use of Cord Blood in Non-Hematologic Applications
- Standardization of Regulatory Frameworks Enhances Global Market Credibility
- Surge in Stem Cell Clinical Trials Broadens Therapeutic Indications and Market Potential
- Awareness Campaigns and Obstetrician Recommendations Increase Collection Rates
- Strategic Collaborations With Hospitals Facilitate On-Site Collection Services
- Increased Investments in Stem Cell Research Strengthen Commercial Viability
- Innovation in Cell Expansion and Differentiation Techniques Enhances Utility of Stored Cells
- 4. GLOBAL MARKET PERSPECTIVE
- TABLE 1: World Stem Cell Umbilical Cord Blood Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
- TABLE 2: World Recent Past, Current & Future Analysis for Stem Cell Umbilical Cord Blood by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 3: World Historic Review for Stem Cell Umbilical Cord Blood by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 4: World 16-Year Perspective for Stem Cell Umbilical Cord Blood by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2025 & 2030
- TABLE 5: World Recent Past, Current & Future Analysis for Pharmaceuticals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 6: World Historic Review for Pharmaceuticals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 7: World 16-Year Perspective for Pharmaceuticals End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2025 & 2030
- TABLE 8: World Recent Past, Current & Future Analysis for Research Institutes End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 9: World Historic Review for Research Institutes End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 10: World 16-Year Perspective for Research Institutes End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2025 & 2030
- TABLE 11: World Recent Past, Current & Future Analysis for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 12: World Historic Review for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 13: World 16-Year Perspective for Hospitals End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2025 & 2030
- TABLE 14: World Recent Past, Current & Future Analysis for Biobanks End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 15: World Historic Review for Biobanks End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 16: World 16-Year Perspective for Biobanks End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2025 & 2030
III. MARKET ANALYSIS
- UNITED STATES
- Stem Cell Umbilical Cord Blood Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
- TABLE 17: USA Recent Past, Current & Future Analysis for Stem Cell Umbilical Cord Blood by End-Use - Pharmaceuticals End-Use, Research Institutes End-Use, Hospitals End-Use and Biobanks End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 18: USA Historic Review for Stem Cell Umbilical Cord Blood by End-Use - Pharmaceuticals End-Use, Research Institutes End-Use, Hospitals End-Use and Biobanks End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 19: USA 16-Year Perspective for Stem Cell Umbilical Cord Blood by End-Use - Percentage Breakdown of Value Sales for Pharmaceuticals End-Use, Research Institutes End-Use, Hospitals End-Use and Biobanks End-Use for the Years 2014, 2025 & 2030
- CANADA
- TABLE 20: Canada Recent Past, Current & Future Analysis for Stem Cell Umbilical Cord Blood by End-Use - Pharmaceuticals End-Use, Research Institutes End-Use, Hospitals End-Use and Biobanks End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 21: Canada Historic Review for Stem Cell Umbilical Cord Blood by End-Use - Pharmaceuticals End-Use, Research Institutes End-Use, Hospitals End-Use and Biobanks End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 22: Canada 16-Year Perspective for Stem Cell Umbilical Cord Blood by End-Use - Percentage Breakdown of Value Sales for Pharmaceuticals End-Use, Research Institutes End-Use, Hospitals End-Use and Biobanks End-Use for the Years 2014, 2025 & 2030
- JAPAN
- Stem Cell Umbilical Cord Blood Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
- TABLE 23: Japan Recent Past, Current & Future Analysis for Stem Cell Umbilical Cord Blood by End-Use - Pharmaceuticals End-Use, Research Institutes End-Use, Hospitals End-Use and Biobanks End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 24: Japan Historic Review for Stem Cell Umbilical Cord Blood by End-Use - Pharmaceuticals End-Use, Research Institutes End-Use, Hospitals End-Use and Biobanks End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 25: Japan 16-Year Perspective for Stem Cell Umbilical Cord Blood by End-Use - Percentage Breakdown of Value Sales for Pharmaceuticals End-Use, Research Institutes End-Use, Hospitals End-Use and Biobanks End-Use for the Years 2014, 2025 & 2030
- CHINA
- Stem Cell Umbilical Cord Blood Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
- TABLE 26: China Recent Past, Current & Future Analysis for Stem Cell Umbilical Cord Blood by End-Use - Pharmaceuticals End-Use, Research Institutes End-Use, Hospitals End-Use and Biobanks End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 27: China Historic Review for Stem Cell Umbilical Cord Blood by End-Use - Pharmaceuticals End-Use, Research Institutes End-Use, Hospitals End-Use and Biobanks End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 28: China 16-Year Perspective for Stem Cell Umbilical Cord Blood by End-Use - Percentage Breakdown of Value Sales for Pharmaceuticals End-Use, Research Institutes End-Use, Hospitals End-Use and Biobanks End-Use for the Years 2014, 2025 & 2030
- EUROPE
- Stem Cell Umbilical Cord Blood Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
- TABLE 29: Europe Recent Past, Current & Future Analysis for Stem Cell Umbilical Cord Blood by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 30: Europe Historic Review for Stem Cell Umbilical Cord Blood by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 31: Europe 16-Year Perspective for Stem Cell Umbilical Cord Blood by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2025 & 2030
- TABLE 32: Europe Recent Past, Current & Future Analysis for Stem Cell Umbilical Cord Blood by End-Use - Pharmaceuticals End-Use, Research Institutes End-Use, Hospitals End-Use and Biobanks End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 33: Europe Historic Review for Stem Cell Umbilical Cord Blood by End-Use - Pharmaceuticals End-Use, Research Institutes End-Use, Hospitals End-Use and Biobanks End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 34: Europe 16-Year Perspective for Stem Cell Umbilical Cord Blood by End-Use - Percentage Breakdown of Value Sales for Pharmaceuticals End-Use, Research Institutes End-Use, Hospitals End-Use and Biobanks End-Use for the Years 2014, 2025 & 2030
- FRANCE
- Stem Cell Umbilical Cord Blood Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
- TABLE 35: France Recent Past, Current & Future Analysis for Stem Cell Umbilical Cord Blood by End-Use - Pharmaceuticals End-Use, Research Institutes End-Use, Hospitals End-Use and Biobanks End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 36: France Historic Review for Stem Cell Umbilical Cord Blood by End-Use - Pharmaceuticals End-Use, Research Institutes End-Use, Hospitals End-Use and Biobanks End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 37: France 16-Year Perspective for Stem Cell Umbilical Cord Blood by End-Use - Percentage Breakdown of Value Sales for Pharmaceuticals End-Use, Research Institutes End-Use, Hospitals End-Use and Biobanks End-Use for the Years 2014, 2025 & 2030
- GERMANY
- Stem Cell Umbilical Cord Blood Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
- TABLE 38: Germany Recent Past, Current & Future Analysis for Stem Cell Umbilical Cord Blood by End-Use - Pharmaceuticals End-Use, Research Institutes End-Use, Hospitals End-Use and Biobanks End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 39: Germany Historic Review for Stem Cell Umbilical Cord Blood by End-Use - Pharmaceuticals End-Use, Research Institutes End-Use, Hospitals End-Use and Biobanks End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 40: Germany 16-Year Perspective for Stem Cell Umbilical Cord Blood by End-Use - Percentage Breakdown of Value Sales for Pharmaceuticals End-Use, Research Institutes End-Use, Hospitals End-Use and Biobanks End-Use for the Years 2014, 2025 & 2030
- ITALY
- TABLE 41: Italy Recent Past, Current & Future Analysis for Stem Cell Umbilical Cord Blood by End-Use - Pharmaceuticals End-Use, Research Institutes End-Use, Hospitals End-Use and Biobanks End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 42: Italy Historic Review for Stem Cell Umbilical Cord Blood by End-Use - Pharmaceuticals End-Use, Research Institutes End-Use, Hospitals End-Use and Biobanks End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 43: Italy 16-Year Perspective for Stem Cell Umbilical Cord Blood by End-Use - Percentage Breakdown of Value Sales for Pharmaceuticals End-Use, Research Institutes End-Use, Hospitals End-Use and Biobanks End-Use for the Years 2014, 2025 & 2030
- UNITED KINGDOM
- Stem Cell Umbilical Cord Blood Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
- TABLE 44: UK Recent Past, Current & Future Analysis for Stem Cell Umbilical Cord Blood by End-Use - Pharmaceuticals End-Use, Research Institutes End-Use, Hospitals End-Use and Biobanks End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 45: UK Historic Review for Stem Cell Umbilical Cord Blood by End-Use - Pharmaceuticals End-Use, Research Institutes End-Use, Hospitals End-Use and Biobanks End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 46: UK 16-Year Perspective for Stem Cell Umbilical Cord Blood by End-Use - Percentage Breakdown of Value Sales for Pharmaceuticals End-Use, Research Institutes End-Use, Hospitals End-Use and Biobanks End-Use for the Years 2014, 2025 & 2030
- REST OF EUROPE
- TABLE 47: Rest of Europe Recent Past, Current & Future Analysis for Stem Cell Umbilical Cord Blood by End-Use - Pharmaceuticals End-Use, Research Institutes End-Use, Hospitals End-Use and Biobanks End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 48: Rest of Europe Historic Review for Stem Cell Umbilical Cord Blood by End-Use - Pharmaceuticals End-Use, Research Institutes End-Use, Hospitals End-Use and Biobanks End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 49: Rest of Europe 16-Year Perspective for Stem Cell Umbilical Cord Blood by End-Use - Percentage Breakdown of Value Sales for Pharmaceuticals End-Use, Research Institutes End-Use, Hospitals End-Use and Biobanks End-Use for the Years 2014, 2025 & 2030
- ASIA-PACIFIC
- Stem Cell Umbilical Cord Blood Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
- TABLE 50: Asia-Pacific Recent Past, Current & Future Analysis for Stem Cell Umbilical Cord Blood by End-Use - Pharmaceuticals End-Use, Research Institutes End-Use, Hospitals End-Use and Biobanks End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 51: Asia-Pacific Historic Review for Stem Cell Umbilical Cord Blood by End-Use - Pharmaceuticals End-Use, Research Institutes End-Use, Hospitals End-Use and Biobanks End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 52: Asia-Pacific 16-Year Perspective for Stem Cell Umbilical Cord Blood by End-Use - Percentage Breakdown of Value Sales for Pharmaceuticals End-Use, Research Institutes End-Use, Hospitals End-Use and Biobanks End-Use for the Years 2014, 2025 & 2030
- REST OF WORLD
- TABLE 53: Rest of World Recent Past, Current & Future Analysis for Stem Cell Umbilical Cord Blood by End-Use - Pharmaceuticals End-Use, Research Institutes End-Use, Hospitals End-Use and Biobanks End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 54: Rest of World Historic Review for Stem Cell Umbilical Cord Blood by End-Use - Pharmaceuticals End-Use, Research Institutes End-Use, Hospitals End-Use and Biobanks End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 55: Rest of World 16-Year Perspective for Stem Cell Umbilical Cord Blood by End-Use - Percentage Breakdown of Value Sales for Pharmaceuticals End-Use, Research Institutes End-Use, Hospitals End-Use and Biobanks End-Use for the Years 2014, 2025 & 2030
IV. COMPETITION
